Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Aged
Biomarkers, Tumor
/ analysis
Cytoplasm
/ pathology
Follow-Up Studies
Humans
Immunohistochemistry
Kallikreins
/ blood
Male
Middle Aged
Neoplasm Grading
Oncogene Proteins, Fusion
/ genetics
Prognosis
Prostate
/ cytology
Prostate-Specific Antigen
/ blood
Prostatectomy
Prostatic Neoplasms
/ diagnosis
Survivin
/ analysis
BIRC5
ERG
Survivin
TMA
deletion
prostate cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
04
09
2019
revised:
27
11
2019
accepted:
27
11
2019
pubmed:
2
1
2020
medline:
24
4
2021
entrez:
2
1
2020
Statut:
ppublish
Résumé
Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal prostate epithelium but expression was often reduced in prostate cancers. Among 9492 evaluable prostate cancers, 9% expressed survivin strongly, 19% moderately, 28% weakly, and 44% lacked it. Loss of cytoplasmic survivin was seen in advanced tumor stage, higher Gleason score, preoperative PSA levels, and Ki-67 labeling index, and associated with earlier PSA recurrence (P < .0001). Survivin loss was significantly more common in cancers carrying TMPRSS2:ERG fusions (61% survivin negative) than in ERG wild-type cancers (32% survivin negative; P < .0001). Multivariate analysis revealed that reduced cytoplasmic survivin expression predicted poor prognosis independent from Gleason score, pT, pN, and serum PSA level. This was valid for ERG-positive and ERG-negative cancers. Survivin expression loss even retained its prognostic impact in 1020 PTEN deleted cancers, a group that is already characterized by dismal patient prognosis. In conclusion, reduced survivin expression is associated with more aggressive tumors and inferior prognosis in prostate cancer.
Identifiants
pubmed: 31893572
doi: 10.1002/cam4.2773
pmc: PMC7013067
doi:
Substances chimiques
BIRC5 protein, human
0
Biomarkers, Tumor
0
Oncogene Proteins, Fusion
0
Survivin
0
TMPRSS2-ERG fusion protein, human
0
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1418Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer. 2004 Feb 15;100(4):751-7
pubmed: 14770431
Clin Cancer Res. 2008 Aug 15;14(16):5000-5
pubmed: 18698017
BMC Cancer. 2015 Jul 23;15:538
pubmed: 26202067
N Engl J Med. 2012 Jul 19;367(3):203-13
pubmed: 22808955
Clin Exp Med. 2009 Sep;9(3):207-13
pubmed: 19205619
Cancer Lett. 2001 Feb 10;163(1):109-16
pubmed: 11163114
Pathol Res Pract. 2014 Jan;210(1):30-4
pubmed: 24199968
Mod Pathol. 2003 Jun;16(6):574-83
pubmed: 12808063
Br J Cancer. 2003 Apr 7;88(7):1077-83
pubmed: 12671708
Cancer Res. 2013 May 1;73(9):2795-805
pubmed: 23492366
BMC Cancer. 2010 Jan 15;10:18
pubmed: 20078866
Prostate. 2009 Jun 15;69(9):976-81
pubmed: 19274666
Clin Cancer Res. 2011 Sep 15;17(18):5878-88
pubmed: 21791629
Chin J Cancer. 2017 Aug 17;36(1):65
pubmed: 28818096
Am J Pathol. 1998 Jan;152(1):43-9
pubmed: 9422522
Clin Cancer Res. 2008 Dec 1;14(23):7838-42
pubmed: 19047112
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
Prostate. 2001 Jun 15;48(1):7-15
pubmed: 11391682
Cancer Med. 2020 Feb;9(4):1409-1418
pubmed: 31893572
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
N Engl J Med. 2012 Jul 19;367(3):270-1
pubmed: 22808963
Cancer Lett. 2007 Apr 28;249(1):49-60
pubmed: 17275177
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
J Cell Sci. 2002 Feb 1;115(Pt 3):575-85
pubmed: 11861764
Clin Cancer Res. 2003 Oct 15;9(13):4914-25
pubmed: 14581366
World J Surg. 2012 Jun;36(6):1411-8
pubmed: 22089920
Prostate. 2002 May 1;51(2):133-40
pubmed: 11948968
Cancer. 2007 Mar 15;109(6):1106-13
pubmed: 17311310
BMC Cancer. 2015 Jul 23;15:536
pubmed: 26198101
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1457-62
pubmed: 9990045
J Pathol. 2013 Sep;231(1):130-41
pubmed: 23794398
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1033-42
pubmed: 18977097
Indian J Med Res. 2015 Apr;141(4):389-97
pubmed: 26112839
Nat Rev Cancer. 2003 Jan;3(1):46-54
pubmed: 12509766
Oncol Lett. 2017 Apr;13(4):2437-2441
pubmed: 28454416
J Urol. 2004 May;171(5):1855-60
pubmed: 15076293
Arch Pathol Lab Med. 2004 Jan;128(1):39-43
pubmed: 14692814
Mod Pathol. 2008 Nov;21(11):1371-8
pubmed: 18552821
Eur J Cancer Prev. 2019 Jul;28(4):365-372
pubmed: 29847456
BJU Int. 2017 Feb;119(2):234-238
pubmed: 26940243
Urology. 2008 Dec;72(6):1229-33
pubmed: 18336887
Clin Cancer Res. 2010 Mar 1;16(5):1553-60
pubmed: 20179235
Springerplus. 2016 May 14;5:621
pubmed: 27330887
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286
Histopathology. 2013 Jan;62(2):247-56
pubmed: 23240715